CompuMed Teams With The Jessica Clinton MVP Foundation for "Cardio Days"

/ Source: GlobeNewswire

LOS ANGELES, March 14, 2011 (GLOBE NEWSWIRE) -- CompuMed, Inc. (OTCBB:CMPD) (), a telemedicine and medical informatics company, has teamed up with Florida's The Jessica Clinton MVP Foundation to provide CompuMed's electrocardiogram (ECG) telemedicine and CardioGramKids® screenings to the students and student athletes on "Cardio Days." CompuMed's CardioGramKids program was designed in tandem with pediatricians and other healthcare providers. It provides ECG screening services with over-reads performed remotely by pediatric cardiologists to children and teenagers prior to taking psychotropic medications or participating in school or afterschool sports programs. The Jessica Clinton MVP Foundation was formed in December 2003 by parents Ramon & Cheryl Lalloo after losing their daughter Jessica to sudden cardiac arrest while cheerleading.

"The Jessica Clinton MVP Foundation has done so much to help save the lives of children in Florida. We have mutual goals of bringing better health to children of all ages. Teaming up creates a valuable partnership," said Maurizio Vecchione, CEO of CompuMed.

"We'd focused successful efforts in getting defibrillators in all schools in Florida but we realize it would be fantastic to find the kids with heart problems before they need a defibrillator. Teaming up with CompuMed to provide ECGs to kids first makes perfect sense," said Cheryl Lalloo, the Founder of The Jessica Clinton MVP Foundation.

"We plan to work with the Foundation to have a Cardio Day in the city where Jessica died, and then encourage schools to do ECG screening days as well," said Maurizio Vecchione, CEO of CompuMed.

About CompuMed

CompuMed, Inc. (OTCBB:CMPD) develops and markets products and services that combine advanced imaging with medical informatics. Its focus is on analysis and remote monitoring for patients with cardiovascular and musculoskeletal diseases. The company has specialized expertise and intellectual property in telemonitoring imaging and analysis designed to improve healthcare provider workflow and patient care while reducing costs. CompuMed is headquartered in Los Angeles and distributes its products worldwide both directly and through OEM partners. Visit CompuMed at and follow at Twitter: @compumed.

The Jessica Clinton MVP Foundation

The Jessica Clinton MVP Foundation was formed in Dec. 2003, co-founded by Ramon & Cheryl Lalloo, after the loss of their daughter Jessica. On Oct. 2nd, 2003, while taking a break during cheerleading practice, Jessica went into Sudden Cardiac Arrest. Although CPR was performed, they were unable to resuscitate her. Jessica had numerous sports physicals and was never diagnosed with any heart conditions. It was discovered that Jessica had an undiagnosed heart condition called Mitral Valve Prolapse. Since then The Jessica Clinton MVP Foundation have been working with local school boards to provide A.E.D.'s to the schools and develop training programs for their faculty. The Foundation has directly donated over 60 defibrillators to local schools and parks. The Foundation has also participated in the deployment of hundreds of defibrillators in the State of Florida. In addition, the Foundation has provided CPR/AED training for hundreds of faculty members and to the general public. In 2006, in a joint effort with the American Heart Association, the Foundation successfully lobbied to have a bill passed requiring all high schools in the State of Florida which participate in an athletic program to have at least one defibrillator on the premises. In 2007 The Foundation received the "Jefferson Award" for public service. The Foundation is committed in taking progressive steps to reduce the risk of losing our children unnecessarily to Sudden Cardiac Arrest. More info at .

Forward-Looking Statements

Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.

CONTACT: Press Contact: Susan Tellem Tellem Worldwide +1 310-313-3444